(NP (NP Glucocorticoid/NN receptor/NN characteristics/NNS) (PP in/IN (NP (NP monocytes/NNS) (PP of/IN (NP (NP patients/NNS) (PP with/IN (NP corticosteroid-resistant/JJ bronchial/JJ asthma/NN)))))) ./.)
(S (NP-SBJ-46 (NP The/DT mechanism/NN) (PP of/IN (NP corticosteroid/NN resistance/NN)) (PP in/IN (NP bronchial/JJ asthma/NN))) (VP has/VBZ (VP been/VBN (VP studied/VBN (NP *-46/-NONE-) (PP by/IN (S (NP-SBJ */-NONE-) (VP determining/VBG (NP (NP the/DT rank/NN order/NN) (PP of/IN (NP potency/NN)) (PP for/IN (NP different/JJ corticosteroids/NNS)) (PP in/IN (S (NP-SBJ */-NONE-) (VP (VP inhibiting/VBG (NP (NP the/DT generation/NN) (PP of/IN (NP a/DT (ADJP 3/CD kD/NN) molecule/NN)) (PP from/IN (NP (NP peripheral/JJ blood/NN monocytes/NNS) (VP isolated/VBN (NP */-NONE-) (PP from/IN (NP (NP (ADJP-COOD (ADJP (ADJP corticosteroid-sensitive/JJ) (PRN -LRB-/-LRB- (ADJP CS/JJ) -RRB-/-RRB-)) and/CC (ADJP (ADJP corticosteroid-resistant/JJ) (PRN -LRB-/-LRB- (ADJP CR/JJ) -RRB-/-RRB-))) asthmatic/JJ subjects/NNS)))))))) ,/, (SBAR (WHNP-47 which/WDT) (S (NP-SBJ *T*-47/-NONE-) (VP augments/VBZ (NP (NP (NP (NP leukotriene/NN B4/NN) (PRN -LRB-/-LRB- (NP LTB4/NN) -RRB-/-RRB-)) generation/NN) (PP by/IN (NP (NP (NP human/JJ neutrophils/NNS) (PRN -LRB-/-LRB- (NP PMN/NN) -RRB-/-RRB-)) (VP stimulated/VBN (NP */-NONE-) (PP by/IN (NP calcium/NN ionophore/NN))))))))))))))))))) ./.)
(S (PP In/IN (NP addition/NN)) ,/, (NP-SBJ-49 (NP binding/VBG studies/NNS) (PP with/IN (NP -LRB-/-LRB- 3H/NN -RRB-/-RRB- dexamethasone/NN))) (VP have/VBP (VP been/VBN (VP performed/VBN (NP *-49/-NONE-) (S (NP-SBJ */-NONE-) (VP to/TO (VP determine/VB (NP (NP-COOD (NP (NP the/DT dissociation/NN constant/NN) (PRN -LRB-/-LRB- (NP Kd/NN) -RRB-/-RRB-)) and/CC (NP (NP receptor/NN numbers/NNS) (PRN -LRB-/-LRB- (NP Ro/NN) -RRB-/-RRB-))) (PP in/IN (NP (NP the/DT monocytes/NNS) (PP of/IN (NP (NP these/DT two/CD groups/NNS) (PP of/IN (NP subjects/NNS))))))))))))) ./.)
(S (NP-SBJ (NP The/DT concentration/NN) (PP of/IN (NP (NP corticosteroid/NN) (VP producing/VBG (NP (NP 50/CD %/NN inhibition/NN) (PRN -LRB-/-LRB- (NP IC50/NN) -RRB-/-RRB-)))))) (VP was/VBD (NP-PRD-COOD (NP (NP-54 600/CD nM/NN) (PP *ICH*-50/-NONE-)) ,/, (NP (NP=54 70/CD nM/NN) (NP=51 *ICH*-52/-NONE-)) ,/, and/CC (NP (NP=54 0.5/CD nM/NN) (NP=51 *ICH*-53/-NONE-))) (PP-50 for/IN (NP-51 hydrocortisone/NN)) ,/, (NP-52 methylprednisolone/NN) ,/, and/CC (NP-53 dexamethasone/NN) ,/, (ADVP respectively/RB) ,/, (PP in/IN (NP (NP monocytes/NNS) (PP from/IN (NP CS/JJ individuals/NNS))))) ./.)
(S (NP-SBJ There/EX) (VP was/VBD (NP-PRD (NP (ADJP only/RB weak/JJ) inhibition/NN) (PP of/IN (NP (NP the/DT generation/NN) (PP of/IN (NP enhancing/NN activity/NN)))) (PP by/IN (NP the/DT corticosteroids/NNS))) (PP in/IN (NP the/DT (ADJP CR/JJ asthmatic/JJ) individuals/NNS))) ./.)
(S (NP-SBJ The/DT dexamethasone/NN Kd/NN) (VP (VP-COOD (VP was/VBD (NP-PRD-55 (NP (QP 2.45/CD +\/-/CC 0.58/CD) nM/NN) (PRN -LRB-/-LRB- (NP-COOD (NP mean/NN) +\/-/CC (NP SEM/NN)) ,/, (S (NP-SBJ n/NN) (VP =/JJ (NP-PRD 6/CD))) -RRB-/-RRB-)) (PP-56 in/IN (NP the/DT (NP CS/JJ) group/NN))) and/CC (VP (NP-PRD=55 (NP (QP 1.6/CD +\/-/CC 0.35/CD) nM/NN) (PRN -LRB-/-LRB- (NP-COOD (NP mean/NN) +\/-/CC (NP SEM/NN)) ,/, (S (NP-SBJ n/NN) (VP =/JJ (NP-PRD 6/CD))) -RRB-/-RRB-)) (PP=56 in/IN (NP the/DT (NP CR/JJ) group/NN) (PP of/IN (NP patients/NNS))))) (PRN -LRB-/-LRB- (S (NP-SBJ p/NN) (VP =/JJ (NP-PRD 0.14/CD))) -RRB-/-RRB-)) ./.)
(S (NP-SBJ The/DT Ro/NN) (VP (VP-COOD (VP (PP-58 in/IN (NP the/DT CS/JJ group/NN)) was/VBD (NP-PRD-59 (QP 3,605/CD +\/-/CC 984/CD) binding/VBG sites/NNS) (PP-60 per/IN (NP nucleus/NN)) (PRN-61 -LRB-/-LRB- (NP-COOD (NP mean/NN) +\/-/CC (NP SEM/NN)) ,/, (S (NP-SBJ n/NN) (VP =/JJ (NP-PRD 6/CD))) -RRB-/-RRB-)) and/CC (VP (NP-PRD=59 (QP 4,757/CD +\/-/CC 692/CD) binding/VBG sites/NNS) (PP=60 per/IN (NP nucleus/NN)) (PRN=61 -LRB-/-LRB- (NP-COOD (NP mean/NN) +\/-/CC (NP SEM/NN)) ,/, (S (NP-SBJ n/NN) (VP =/JJ (NP-PRD 6/CD))) -RRB-/-RRB-) (PP=58 in/IN (NP the/DT CR/JJ group/NN)))) (PRN -LRB-/-LRB- (S (NP-SBJ p/NN) (VP =/JJ (NP-PRD 0.23/CD))) -RRB-/-RRB-)) ./.)
(S (NP-SBJ These/DT findings/NNS) (VP indicate/VBP (SBAR that/IN (S (NP-SBJ-62 (NP corticosteroid/NN resistance/NN) (PP in/IN (NP bronchial/JJ asthma/NN))) (VP can/MD not/RB (VP be/VB (VP explained/VBN (NP *-62/-NONE-) (PP by/IN (NP (NP abnormalities/NNS) (PP in/IN (NP (NP corticosteroid/NN receptor/NN) characteristics/NNS)))))))))) ./.)
